Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Open-label, Parallel-group, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Insulin Aspart Injection in Patients With Diabetes Mellitus Compared to NovoRapid®

NCT02491528 is registered in ClinicalTrials.gov with Tonghua Dongbao Pharmaceutical Co.,Ltd as lead sponsor.

NCT NCT02491528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02491528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Open-label, Parallel-group, Phase Ⅲ Study to Evaluate the Efficacy and Safety of Insulin Aspart Injection in Patients With Diabetes Mellitus Compared to NovoRapid®
Lead sponsor
Tonghua Dongbao Pharmaceutical Co.,Ltd
Phase
Phase 3
Overall status
Completed
Start date
June 19, 2015
Completion date
August 12, 2016
Enrollment
563 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes